As I mentioned, there are a number of concerns that have been raised. We are listening to those who have differing perspectives on prescribed pharmaceutical alternatives. We are also looking at the data and we are evaluating these programs, as is B.C.
Certainly, we are looking to get additional information to better understand the implications of how much diversion is going on, what risk mitigation measures we can put in place and some of the best practices. I can note that, in terms of actions we have taken from Health Canada, we are reviewing and working with our programs to look at those risk mitigation protocols to get a better sense of those.